Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Cancer ; 24(1): 173, 2024 Feb 05.
Article in English | MEDLINE | ID: mdl-38317080

ABSTRACT

Copy-number alterations (CNAs) are a hallmark of cancer and can regulate cancer cell states via altered gene expression values. Herein, we have developed a copy-number impact (CNI) analysis method that quantifies the degree to which a gene expression value is impacted by CNAs and leveraged this analysis at the pathway level. Our results show that a high CNA is not necessarily reflected at the gene expression level, and our method is capable of detecting genes and pathways whose activity is strongly influenced by CNAs. Furthermore, the CNI analysis enables unbiased categorization of CNA categories, such as deletions and amplifications. We identified six CNI-driven pathways associated with poor treatment response in ovarian high-grade serous carcinoma (HGSC), which we found to be the most CNA-driven cancer across 14 cancer types. The key driver in most of these pathways was amplified wild-type KRAS, which we validated functionally using CRISPR modulation. Our results suggest that wild-type KRAS amplification is a driver of chemotherapy resistance in HGSC and may serve as a potential treatment target.


Subject(s)
Carcinoma , Ovarian Neoplasms , Female , Humans , Ovarian Neoplasms/pathology , Proto-Oncogene Proteins p21(ras)/genetics , Genome , DNA Copy Number Variations , Carcinoma/genetics , Gene Expression
2.
Cancer Cell ; 41(6): 1103-1117.e12, 2023 06 12.
Article in English | MEDLINE | ID: mdl-37207655

ABSTRACT

Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and morphological phenotypes, and significant association with treatment response. Nested pathway analysis suggests two evolutionary trajectories between the states. Experiments with five tumor organoids and three PI3K inhibitors support targeting tumors with enriched PI3K/AKT pathway with alpelisib. Heterogeneity analysis of samples from multiple anatomical sites shows that site-of-origin samples have 70% more unique clones than metastatic tumors or ascites. In conclusion, these analysis and visualization methods enable integrative tumor evolution analysis to identify patient subtypes using data from longitudinal, multiregion cohorts.


Subject(s)
Cystadenocarcinoma, Serous , Fallopian Tube Neoplasms , Ovarian Neoplasms , Female , Humans , Ovarian Neoplasms/pathology , Phosphatidylinositol 3-Kinases/genetics , Prospective Studies , Cystadenocarcinoma, Serous/metabolism , Fallopian Tube Neoplasms/genetics
3.
Lab Invest ; 102(7): 753-761, 2022 07.
Article in English | MEDLINE | ID: mdl-35169222

ABSTRACT

RNA in situ hybridization (RNA-ISH) is a powerful spatial transcriptomics technology to characterize target RNA abundance and localization in individual cells. This allows analysis of tumor heterogeneity and expression localization, which are not readily obtainable through transcriptomic data analysis. RNA-ISH experiments produce large amounts of data and there is a need for automated analysis methods. Here we present QuantISH, a comprehensive open-source RNA-ISH image analysis pipeline that quantifies marker expressions in individual carcinoma, immune, and stromal cells on chromogenic or fluorescent in situ hybridization images. QuantISH is designed to be modular and can be adapted to various image and sample types and staining protocols. We show that in chromogenic RNA in situ hybridization images of high-grade serous carcinoma (HGSC) QuantISH cancer cell classification has high precision, and signal expression quantification is in line with visual assessment. We further demonstrate the power of QuantISH by showing that CCNE1 average expression and DDIT3 expression variability, as captured by the variability factor developed herein, act as candidate biomarkers in HGSC. Altogether, our results demonstrate that QuantISH can quantify RNA expression levels and their variability in carcinoma cells, and thus paves the way to utilize RNA-ISH technology.


Subject(s)
Biomarkers, Tumor , RNA , Biomarkers, Tumor/metabolism , Gene Expression Profiling , In Situ Hybridization , In Situ Hybridization, Fluorescence/methods , RNA/genetics
4.
Sci Adv ; 8(8): eabm1831, 2022 02 25.
Article in English | MEDLINE | ID: mdl-35196078

ABSTRACT

Chemotherapy resistance is a critical contributor to cancer mortality and thus an urgent unmet challenge in oncology. To characterize chemotherapy resistance processes in high-grade serous ovarian cancer, we prospectively collected tissue samples before and after chemotherapy and analyzed their transcriptomic profiles at a single-cell resolution. After removing patient-specific signals by a novel analysis approach, PRIMUS, we found a consistent increase in stress-associated cell state during chemotherapy, which was validated by RNA in situ hybridization and bulk RNA sequencing. The stress-associated state exists before chemotherapy, is subclonally enriched during the treatment, and associates with poor progression-free survival. Co-occurrence with an inflammatory cancer-associated fibroblast subtype in tumors implies that chemotherapy is associated with stress response in both cancer cells and stroma, driving a paracrine feed-forward loop. In summary, we have found a resistant state that integrates stromal signaling and subclonal evolution and offers targets to overcome chemotherapy resistance.


Subject(s)
Drug Resistance, Neoplasm , Ovarian Neoplasms , Drug Resistance, Neoplasm/genetics , Female , Humans , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/genetics , Ovarian Neoplasms/pathology , Sequence Analysis, RNA , Transcriptome , Exome Sequencing
5.
Nat Commun ; 12(1): 3904, 2021 06 23.
Article in English | MEDLINE | ID: mdl-34162871

ABSTRACT

Due to its dynamic nature, the evolution of cancer cell-extracellular matrix (ECM) crosstalk, critically affecting metastasis and treatment resistance, remains elusive. Our results show that platinum-chemotherapy itself enhances resistance by progressively changing the cancer cell-intrinsic adhesion signaling and cell-surrounding ECM. Examining ovarian high-grade serous carcinoma (HGSC) transcriptome and histology, we describe the fibrotic ECM heterogeneity at primary tumors and distinct metastatic sites, prior and after chemotherapy. Using cell models from systematic ECM screen to collagen-based 2D and 3D cultures, we demonstrate that both specific ECM substrates and stiffness increase resistance to platinum-mediated, apoptosis-inducing DNA damage via FAK and ß1 integrin-pMLC-YAP signaling. Among such substrates around metastatic HGSCs, COL6 was upregulated by chemotherapy and enhanced the resistance of relapse, but not treatment-naïve, HGSC organoids. These results identify matrix adhesion as an adaptive response, driving HGSC aggressiveness via co-evolving ECM composition and sensing, suggesting stromal and tumor strategies for ECM pathway targeting.


Subject(s)
Cystadenocarcinoma, Serous/genetics , Drug Resistance, Neoplasm/genetics , Gene Expression Profiling/methods , Gene Expression Regulation, Neoplastic , Ovarian Neoplasms/genetics , Antineoplastic Agents/therapeutic use , Apoptosis/drug effects , Apoptosis/genetics , Cell Adhesion/drug effects , Cell Adhesion/genetics , Cell Line, Tumor , Cisplatin/therapeutic use , Collagen/genetics , Collagen/metabolism , Cystadenocarcinoma, Serous/metabolism , Cystadenocarcinoma, Serous/pathology , Evolution, Molecular , Extracellular Matrix/drug effects , Extracellular Matrix/metabolism , Female , Humans , Kaplan-Meier Estimate , Neoplasm Recurrence, Local , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/pathology , Signal Transduction/drug effects , Signal Transduction/genetics , Tumor Microenvironment/drug effects , Tumor Microenvironment/genetics
6.
Iran J Public Health ; 42(11): 1259-65, 2013 Nov.
Article in English | MEDLINE | ID: mdl-26171338

ABSTRACT

BACKGROUND: Awareness of hyperdontia pattern/prevalence can be useful in early diagnosis and prevention by general practitioners, pediatric dentists, and orthodontists. Since the previous results regarding the pattern of hyperdontia (supernumerary teeth) are controversial, this study aimed to assess this subject among Iranian orthodontic patients. METHODS: All approved panoramic radiographs of 3374 orthodontic patients (aged 10 to 20 years old) who had visited orthodontic departments of all Tehran dentistry universities and 10 private clinics during the years 1999-2009 were investigated to establish the prevalence/pattern of hyperdontia in permanent dentition (excluding third molars). The data were analyzed using a chi-square, a chi-square goodness-of-fit, and a Fisher exact test (α=0.05). RESULTS: Of the patients, 2012 were female and 1362 were male. The prevalence of hyperdontia was 0.72% (14 females [0.69% of females], 10 males [0.73% of males], female-to-male ratio=1:1.055). The difference between the genders was not significant (P = 0.896). No double or multiple supernumeraries were found. The most common accessory teeth were mesiodens (58.3%), maxillary laterals (25%), and maxillary premolars (16.7%). Hyperdontia was significantly more common (P=0.000) in maxilla (there was only one mandibular accessory tooth). It was more frequent in the anterior segment (P=0.000). However the occurrence was not significantly different between bimaxillary right and left quadrants (P=0.6). CONCLUSION: Hyperdontia was more common in premaxilla, and the most common accessory tooth was mesiodens. Unlike earlier studies, no bilateral accessory teeth were found. Also no gender dimorphism was discerned.

SELECTION OF CITATIONS
SEARCH DETAIL
...